Study Information
Study Details
View study details on clinicaltrials.gov.
Locations
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
A prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
Location: SIMR (Sacramento/Valley Area)
Please contact:SIMR@sutterhealth.org about Locally Advanced Panreatic Panova-3
Principal Investigator
Related Studies
Cancer Liquid Biopsy Monitoring Study
Investigators: Deepti Behl, MD, Mohammed Kashani-Sabet, M.D.
COVID-19 Impacts on Cancer Care Management, Patient Experience and Care Costs
Investigators: Su-Ying Liang, Ph.D., Monique de Bruin, M.D., MPH, Cheryl Stults, Ph.D.
Stupski Serious Illness Program Evaluation
Investigator: Sylvia Sudat, PhD
Impact of COVID-19 on Cancer Care Management
Investigators: Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D.
Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related Conditions
Investigator: Su-Ying Liang, Ph.D.
Improving Cancer Care
Investigator: Su-Ying Liang, Ph.D.
Multilevel Study of Lung Cancer Screening Guidelines Implementation (MUST)
Investigator: Jiang Li, Ph.D., MPH
Implementing Universal Lynch Syndrome Screening Across Multiple Healthcare Systems: Identifying Strategies to Facilitate and Maintain Programs in Different Organizations Contexts
Investigators: External PI, Principal Investigator, Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D.
Lung Cancer in Never Smokers: Incidence, Risk Factors and Molecular Characteristics in Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Women
Investigators: External PI, Principal Investigator, Su-Ying Liang, Ph.D.